Mineralys Therapeutics presents lorundrostat data in uncontrolled and resistant hypertension
MLYS•Mineralys Therapeutics reported a placebo-adjusted systolic blood pressure reduction of 11.6 mmHg after six weeks of 50 mg lorundrostat and highlighted a Dec. 22, 2026 PDUFA target date.
1. Lorundrostat data
Mineralys Therapeutics said lorundrostat delivered a placebo-adjusted systolic blood pressure reduction of 11.6 mmHg at six weeks with a 50 mg dose. The company highlighted a Dec. 22, 2026, PDUFA target date in its corporate presentation.
2. Market and cash
The company estimates the targeted U.S. market at 20 million patients with uncontrolled or resistant hypertension. Its cash balance was $625 million as of Sept. 30, 2026.
